retatrutide phase 2 trial VisualAbstract: reduces body weight by 17.5% in patients with obesity Lilly's triple agonist delivers up

Retatrutide is a triple-action incretin receptor agonist currently undergoing Phase 2 and Phase 3 clinical trials for obesity and type 2 diabetes

First, the Company has resubmitted to the FDA its new drug application (NDA) for dihydroergotamine (DHE) prefilled syringe autoinjector for the acute treatment of migraine with or without aura and cluster headache in adults

Tirzepatide body aches tend to be transient and manageable with adequate hydration, electrolyte supplementation, and gentle movement

, , , GLP-1

The legal status of research peptides varies by jurisdiction, and researchers should understand their local regulations before purchasing